PNPeter J. Nelson

Peter J. Nelson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Peter J. Nelson has a total of 28 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Supplementary Data FS1 from Mesenchymal Stem Cell–mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice

    by Carolin Kitzberger, Rebekka Spellerberg, Yang Han, Kathrin A. Schmohl, Christina Stauss, Christian Zach, Roland E. Kälin, Gabriele Multhoff, Matthias Eiber, Franz Schilling, et al.

    Supplementary Figure 1: Radioiodide uptake of GL261 brain tumors after systemic MSC-mediated NIS reporter gene delivery in comparison to thyroid as endogenous NIS-expressing organ assessed by 124I PET/CT imaging. Results are expressed as mean value ± SEM.Supplementary Figure 2: Ex vivo analysis of non-target organs after NIS-MSC gene delivery. NIS (A) and Neomycin (B; selection marker of NIS-MSCs) mRNA expression was detected by qPCR in liver, spleen, kidney and lung after NIS-MSC application and showed no expression above the background level of untreated tumors (which was arbitrarily set to one; NIS mRNA levels of untreated ΔΔCt = 0.0003 and Neomycin mRNA levels of untreated ΔΔCt = 0.002). Data are represented as mean-fold change ± SEM (*p<0.05).

  • Open Access

    Data from Mesenchymal Stem Cell–mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice

    by Carolin Kitzberger, Rebekka Spellerberg, Yang Han, Kathrin A. Schmohl, Christina Stauss, Christian Zach, Roland E. Kälin, Gabriele Multhoff, Matthias Eiber, Franz Schilling, et al.

    Purpose:Mesenchymal stem cells (MSC) have emerged as cellular-based vehicles for the delivery of therapeutic genes in cancer therapy based on their inherent tumor-homing capability. As theranostic gene, the sodium iodide symporter (NIS) represents a successful target for noninvasive radionuclide-based imaging and therapy. In this study, we applied genetically engineered MSCs for tumor-targeted NIS gene transfer in experimental glioblastoma (GBM)—a tumor with an extremely poor prognosis.Experimental Design:A syngeneic, immunocompetent GL261 GBM mouse model was established by subcutaneous and orthotopic implantation. Furthermore, a subcutaneous xenograft U87 model was used. Bone marrow–derived MSCs were stably transfected with a NIS-expressing plasmid driven by the constitutively active cytomegalovirus promoter (NIS-MSC). After multiple or single intravenous injection of NIS-MSCs, tumoral iodide uptake was monitored in vivo using 123I-scintigraphy or 124I-PET. Following validation of functional NIS expression, a therapy trial with 131I was performed on the basis of the most optimal application regime as seen by 124I-PET imaging in the orthotopic approach.Results:A robust tumoral NIS-specific radionuclide accumulation was observed after NIS-MSC and radioiodide application by NIS-mediated in vivo imaging. NIS immunofluorescence staining of GBM and non-target tissues showed tumor-selective MSC homing along with NIS expression. Application of therapeutically effective 131I led to significantly delayed tumor growth and prolonged median survival after NIS-MSC treatment as compared with controls.Conclusions:A strong tumor-selective recruitment of systemically applied MSCs into GBM was found using NIS as reporter gene followed by successful therapeutic application of radioiodide demonstrating the potential use of NIS-based MSCs as therapy vehicles as a new GBM therapy approach.

  • Open Access

    Supplementary Data FS1 from Mesenchymal Stem Cell–mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice

    by Carolin Kitzberger, Rebekka Spellerberg, Yang Han, Kathrin A. Schmohl, Christina Stauss, Christian Zach, Roland E. Kälin, Gabriele Multhoff, Matthias Eiber, Franz Schilling, et al.

    Supplementary Figure 1: Radioiodide uptake of GL261 brain tumors after systemic MSC-mediated NIS reporter gene delivery in comparison to thyroid as endogenous NIS-expressing organ assessed by 124I PET/CT imaging. Results are expressed as mean value ± SEM.Supplementary Figure 2: Ex vivo analysis of non-target organs after NIS-MSC gene delivery. NIS (A) and Neomycin (B; selection marker of NIS-MSCs) mRNA expression was detected by qPCR in liver, spleen, kidney and lung after NIS-MSC application and showed no expression above the background level of untreated tumors (which was arbitrarily set to one; NIS mRNA levels of untreated ΔΔCt = 0.0003 and Neomycin mRNA levels of untreated ΔΔCt = 0.002). Data are represented as mean-fold change ± SEM (*p<0.05).

  • Open Access

    Data from Mesenchymal Stem Cell–mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice

    by Carolin Kitzberger, Rebekka Spellerberg, Yang Han, Kathrin A. Schmohl, Christina Stauss, Christian Zach, Roland E. Kälin, Gabriele Multhoff, Matthias Eiber, Franz Schilling, et al.

  • Open Access

    Supplementary Data FS1 from Mesenchymal Stem Cell–mediated Image-guided Sodium Iodide Symporter (NIS) Gene Therapy Improves Survival of Glioblastoma-bearing Mice

    by Carolin Kitzberger, Rebekka Spellerberg, Yang Han, Kathrin A. Schmohl, Christina Stauss, Christian Zach, Roland E. Kälin, Gabriele Multhoff, Matthias Eiber, Franz Schilling, et al.

    Supplementary Figure 1: Radioiodide uptake of GL261 brain tumors after systemic MSC-mediated NIS reporter gene delivery in comparison to thyroid as endogenous NIS-expressing organ assessed by 124I PET/CT imaging. Results are expressed as mean value ± SEM.Supplementary Figure 2: Ex vivo analysis of non-target organs after NIS-MSC gene delivery. NIS (A) and Neomycin (B; selection marker of NIS-MSCs) mRNA expression was detected by qPCR in liver, spleen, kidney and lung after NIS-MSC application and showed no expression above the background level of untreated tumors (which was arbitrarily set to one; NIS mRNA levels of untreated ΔΔCt = 0.0003 and Neomycin mRNA levels of untreated ΔΔCt = 0.002). Data are represented as mean-fold change ± SEM (*p<0.05).

  • DKK3 Promotes Oxidative Stress‒Induced Fibroblast Activity

    by Sabrina Muecklich, Khuram Shehzad, Jessica Tiemann, Li Li, Sonja Leson, Peter J. Nelson, Richard Jennemann, Matthias Klein, Christian Becker, Roger Sandhoff, et al.


  • Mesenchymal Stem Cell–mediated Image-guided Sodium Iodide Symporter ( NIS ) Gene Therapy Improves Survival of Glioblastoma-bearing Mice

    by Carolin Kitzberger, Rebekka Spellerberg, Yang Han, Kathrin A. Schmohl, Christina Stauss, Christian Zach, Roland E. Kälin, Gabriele Multhoff, Matthias Eiber, Franz Schilling, et al.

    Purpose: Mesenchymal stem cells (MSC) have emerged as cellular-based vehicles for the delivery of therapeutic genes in cancer therapy based on their inherent tumor-homing capability. As theranostic gene, the sodium iodide symporter (NIS) represents a successful target for noninvasive radionuclide-based imaging and therapy. In this study, we applied genetically engineered MSCs for tumor-targeted NIS gene transfer in experimental glioblastoma (GBM)—a tumor with an extremely poor prognosis. Experimental Design: A syngeneic, immunocompetent GL261 GBM mouse model was established by subcutaneous and orthotopic implantation. Furthermore, a subcutaneous xenograft U87 model was used. Bone marrow–derived MSCs were stably transfected with a NIS-expressing plasmid driven by the constitutively active cytomegalovirus promoter (NIS-MSC). After multiple or single intravenous injection of NIS-MSCs, tumoral iodide uptake was monitored in vivo using 123I-scintigraphy or 124I-PET. Following validation of functional NIS expression, a therapy trial with 131I was performed on the basis of the most optimal application regime as seen by 124I-PET imaging in the orthotopic approach. Results: A robust tumoral NIS-specific radionuclide accumulation was observed after NIS-MSC and radioiodide application by NIS-mediated in vivo imaging. NIS immunofluorescence staining of GBM and non-target tissues showed tumor-selective MSC homing along with NIS expression. Application of therapeutically effective 131I led to significantly delayed tumor growth and prolonged median survival after NIS-MSC treatment as compared with controls. Conclusions: A strong tumor-selective recruitment of systemically applied MSCs into GBM was found using NIS as reporter gene followed by successful therapeutic application of radioiodide demonstrating the potential use of NIS-based MSCs as therapy vehicles as a new GBM therapy approach.


  • Open Access

    Taking Advantage of the TGFB1 Biology in Differentiated Thyroid Cancer to Stimulate Sodium Iodide Symporter (NIS)-Mediated Iodide Uptake in Engineered Mesenchymal Stem Cells

    by Yang Han, Viktoria F Koehler, Nathalie Schwenk, Kathrin A Schmohl, Rebekka Spellerberg, Carolin Kitzberger, Peter J Nelson, Christine Spitzweg

    The sodium iodide symporter (NIS) mediates the active transport of iodide into thyroid follicular cells, providing the basis for the use of radioiodide for diagnostic imaging and therapy of differentiated thyroid cancer and also non-thyroidal tumors after tumor-selective NIS gene transfer. Based on their excellent tumor-homing capacity, mesenchymal stem cells (MSCs) can be employed as tumor-selective NIS gene delivery vehicles. Transgenic expression of NIS in genetically engineered MSCs allows noninvasive imaging of functional NIS expression as well as therapeutic application of 131I. The use of promoters activated by tumor micromilieu-derived signals to drive NIS expression enhances selectivity and effectiveness, while limiting potential off-target effects. In this study we aimed to exploit the central role of transforming growth factor B1 (TGFB1) in tumor milieu-associated signaling using a TGFB1-inducible synthetic SMAD-responsive promoter to selectively drive NIS-transgene expression in engineered MSCs (SMAD-NIS-MSC) in the context of differentiated thyroid cancer based on the critical role of TGFB1 in the pathogenesis of radioiodine refractory differentiated thyroid cancer. To evaluate the TGFB1 expression in thyroid cancer cell lines, the TGFB1 concentration in conditioned medium (CM) from an array of established human papillary thyroid cancer (PTC) cell lines (BCPAP and K1) was measured by ELISA. BCPAP-CM showed a higher concentration of TGFB1, while a lower concentration was measured in K1-CM. Stimulation of SMAD-NIS-MSCs with PTC-CM showed a significant increase of NIS-mediated radioiodide-125 uptake in these MSCs in vitro. In addition, iodide uptake in SMAD-NIS-MSCs was significantly stimulated by co-culture with thyroid cancer cells. Cell migration assay was performed to validate the effect of PTC-CM in MSC recruitment. MSCs subjected to a gradient between tumor CM and serum free medium showed a directed chemotaxis towards CM with increased forward migration index (FMI) and center of mass (CoM). In a next step, based on the in vitro studies, SMAD-NIS-MSCs will be systemically applied via the tail vein to mice harboring subcutaneous PTC tumors and tumoral iodide uptake will be monitored by 123I-scintigraphy. Taken together, these data indicate the feasibility of commandeering TGF-β/SMAD signaling in the TGFB1-rich tumor environments of radioiodine refractory differentiated thyroid carcinomas to re-establish functional NIS expression using engineered mesenchymal stem cells as therapy vehicles.